ICCC
ImmuCell Corporation
9.90$
-0.5%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 76.5% | 75.3% | 68.4% | 77.5% | 73.7% | 63.5% | 58.4% | 56.3% | 57.1% | 61.8% | 55.0% | 66.1% | 59.7% | |
| 23.5% | 24.7% | 31.6% | 22.5% | 26.3% | 36.5% | 41.6% | 43.7% | 42.9% | 38.2% | 45.0% | 33.9% | 40.3% | |
| 20.7% | 20.9% | 17.4% | 18.8% | 13.1% | 10.6% | 9.4% | 12.9% | 12.6% | 10.0% | 3.1% | 1.7% | 6.2% | |
| 9.5% | 23.4% | 7.3% | 11.0% | 8.8% | 7.2% | 18.3% | 11.2% | 13.2% | 14.8% | 11.0% | 17.7% | 13.9% | |
| 45.4% | 44.4% | 35.8% | 47.8% | 35.9% | 28.5% | 86.1% | 34.9% | 42.6% | 38.9% | 26.0% | 7.0% | 27.7% | |
| -21.9% | -19.7% | -4.1% | -25.3% | -9.6% | 8.0% | 13.9% | 8.8% | 0.4% | -0.8% | 19.0% | 26.9% | 12.6% | |
| 2.7% | 3.2% | 2.0% | 2.6% | 2.2% | 1.6% | 1.5% | 1.9% | 2.4% | 1.4% | 1.0% | 1.3% | 1.4% | |
| -17.4% | -22.3% | -6.0% | -28.0% | -11.7% | 6.7% | 18.0% | 7.8% | -2.5% | -37.3% | 18.9% | 26.2% | 2.8% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.1% | 0.0% | 0.1% | 0.6% | 0.2% | |
| -17.4% | -22.4% | -6.0% | -28.0% | -11.7% | 6.6% | 17.9% | 7.8% | -2.5% | -37.4% | 18.7% | 25.5% | 2.6% | |
| -1.8% | -6.2% | 5.2% | -13.1% | 1.7% | 17.0% | 22.2% | 20.1% | 9.9% | -26.7% | 24.9% | 34.1% | 11.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.